- Home
- NODK vs DRUG Comparison
NODK vs DRUG Comparison
Compare NODK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- DRUG
- Stock Information
- Founded
- NODK 1946
- DRUG 2019
- Country
- NODK United States
- DRUG United States
- Employees
- NODK N/A
- DRUG N/A
- Industry
- NODK Property-Casualty Insurers
- DRUG Pharmaceuticals and Biotechnology
- Sector
- NODK Finance
- DRUG Health Care
- Exchange
- NODK Nasdaq
- DRUG Nasdaq
- Market Cap
- NODK 290.9M
- DRUG 253.2M
- IPO Year
- NODK 2017
- DRUG N/A
- Fundamental
- Price
- NODK $14.25
- DRUG $36.50
- Analyst Decision
- NODK
- DRUG Strong Buy
- Analyst Count
- NODK 0
- DRUG 4
- Target Price
- NODK N/A
- DRUG $84.33
- AVG Volume (30 Days)
- NODK 21.1K
- DRUG 39.0K
- Earning Date
- NODK 03-07-2025
- DRUG 05-16-2025
- Dividend Yield
- NODK N/A
- DRUG N/A
- EPS Growth
- NODK N/A
- DRUG N/A
- EPS
- NODK N/A
- DRUG N/A
- Revenue
- NODK $325,204,000.00
- DRUG N/A
- Revenue This Year
- NODK N/A
- DRUG N/A
- Revenue Next Year
- NODK N/A
- DRUG N/A
- P/E Ratio
- NODK $45.81
- DRUG N/A
- Revenue Growth
- NODK 6.97
- DRUG N/A
- 52 Week Low
- NODK $13.47
- DRUG $0.93
- 52 Week High
- NODK $17.24
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- NODK 49.53
- DRUG 52.51
- Support Level
- NODK $14.00
- DRUG $35.35
- Resistance Level
- NODK $14.36
- DRUG $37.90
- Average True Range (ATR)
- NODK 0.26
- DRUG 2.23
- MACD
- NODK 0.04
- DRUG 0.24
- Stochastic Oscillator
- NODK 70.00
- DRUG 76.00
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.